Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.73 |
| ▸ | MEN1 | O00255 | 2/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.70 |
| ▸ | HTR1A | P08908 | 4/20 | 0.68 |
| ▸ | HTR7 | P34969 | 3/20 | 0.68 |
| ▸ | TSHR | P16473 | 3/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.67 |
| ▸ | HTR2A | P28223 | 1/20 | 0.66 |
| ▸ | HTR6 | P50406 | 1/20 | 0.66 |
| ▸ | CA12 | O43570 | 1/20 | 0.64 |
| ▸ | CA1 | P00915 | 1/20 | 0.64 |
| ▸ | CA9 | Q16790 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | RECQL | P46063 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17884620 | 0.88 | MEN1 (0.76) | ALDH1A1MEN1KMT2ASMN1; SMN2HTR1A | |
| SCHEMBL264542 | 0.86 | MEN1 (0.74) | ALDH1A1MEN1KMT2ASMN1; SMN2HTR1A | |
| SCHEMBL19002446 | 0.85 | DRD2 (0.60) | ALDH1A1MEN1KMT2ASMN1; SMN2HTR1A | |
| SCHEMBL12377877 | 0.85 | TSHR (0.61) | ALDH1A1MEN1KMT2ASMN1; SMN2TSHR | |
| SCHEMBL20708381 | 0.84 | TSHR (0.53) | ALDH1A1MEN1KMT2ASMN1; SMN2TSHR | |
| SCHEMBL19002651 | 0.84 | ADAMTS5 (0.58) | ALDH1A1MEN1KMT2ASMN1; SMN2TSHR | |
| SCHEMBL22892232 | 0.84 | ALDH1A1 (0.53) | ALDH1A1MEN1KMT2ASMN1; SMN2HTR1A | |
| SCHEMBL4352910 | 0.84 | MEN1 (0.79) | ALDH1A1MEN1KMT2ASMN1; SMN2HTR1A | |
| SCHEMBL13453343 | 0.83 | HTR1A (0.71) | ALDH1A1MEN1KMT2ASMN1; SMN2HTR1A | |
| SCHEMBL12419699 | 0.83 | AKR1C3 (0.68) | ALDH1A1MEN1KMT2ASMN1; SMN2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1996550-A2 | CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES | Novartis AG (CH) | 2008-12-03 | — | — | EP | claimed |
| WO-2007038459-A2 | CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES | NOVARTIS AG (CH) | 2007-04-05 | — | — | WO | claimed |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | ALDH1A1 2765/4885MEN1 4080/4885KMT2A 3544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.